Biotech entity
All 2 tracked stories fall under one category: pharma. Akamai Technologies is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 25-day window averages about 0.6 stories each week. At 5, the average consequence score sits below the same-window beat average of 6.1.
Last mentioned: Mar 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Akamai Technologies is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 25-day window averages about 0.6 stories each week. At 5, the average consequence score sits below the same-window beat average of 6.1. They are better corroborated than the beat average, carrying 3.5 original sources each against 3.4 for the same window. We currently track 2 Biotech stories that mention Viatris, published between February 25, 2026 and March 21, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 328 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Viatris. Shared-story counts are live from our verified record — not editorial picks.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Viatris (VTRS) and CRA International (CRAI) are scheduled to report Q4 results on February 26, 2026, providing critical insights into the generic drug market and life sciences consulting demand. These reports come as the industry faces significant regulatory and pricing headwinds from the Inflation Reduction Act and a shifting biosimilar landscape.
Viatris is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
